SAN MATEO, Calif., Feb. 9, 2012 (GLOBE NEWSWIRE) -- NeurogesX Inc., a specialty pharmaceutical company focused on developing and commercializing a portfolio of novel non-opioid, pain management, announced that NASDAQ has halted trading on the Company’s common stock (Nasdaq:NGSX).
